Evidence map›Paper›PMID 37668741›Full record

ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2024

Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration.

Keiko Kataoka, Kanako Itagaki, Nozumu Hashiya, Sorako Wakugawa, Koji Tanaka, Makiko Nakayama, Akiko Yamamoto, Ryo Mukai, Jyunichiro Honjyo, Ichiro Maruko and 11 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 2 pooled it
18.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. One-year real-world data of intravitreal faricimab in patients with pre-treated neovascular age-related macular degeneration.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Article
  12. Article
  13. Article
  14. Treatment outcomes of switching to aflibercept 8 mg in previously-treated neovascular age-related macular degeneration.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
  15. Observational
  16. Article
  17. Observational
  18. Article
  19. Efficacy of switching treatment to faricimab in recalcitrant neovascular age related macular degeneration - 6 month results after completion of the loading phase.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 5 institutions in 1 country.

Keiko KataokaDepartment of Ophthalmology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka-shi, Tokyo, Japan. keiko-kataoka@ks.kyorin-u.ac.jp.ORCID http://orcid.org/0000-0002-8795-6536
Kanako ItagakiDepartment of Ophthalmology, Fukushima Medical University, Fukushima, Japan.
Nozumu HashiyaDepartment of Ophthalmology, Tokyo Women's Medical University, Tokyo, Japan.
Sorako WakugawaDepartment of Ophthalmology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.
Koji TanakaDepartment of Ophthalmology, Nihon University School of Medicine, Tokyo, Japan.
Makiko NakayamaDepartment of Ophthalmology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka-shi, Tokyo, Japan.
Akiko YamamotoDepartment of Ophthalmology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka-shi, Tokyo, Japan.
Ryo MukaiDepartment of Ophthalmology, Fukushima Medical University, Fukushima, Japan.
Jyunichiro HonjyoDepartment of Ophthalmology, Fukushima Medical University, Fukushima, Japan.
Ichiro MarukoDepartment of Ophthalmology, Tokyo Women's Medical University, Tokyo, Japan.
Moeko KawaiDepartment of Ophthalmology, Tokyo Women's Medical University, Tokyo, Japan.
Yasunori MiyaraDepartment of Ophthalmology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.
Nobuhiro TeraoDepartment of Ophthalmology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.
Yu WakatsukiDepartment of Ophthalmology, Nihon University School of Medicine, Tokyo, Japan.
Hajime OnoeDepartment of Ophthalmology, Nihon University School of Medicine, Tokyo, Japan.
Ryusaburo MoriDepartment of Ophthalmology, Nihon University School of Medicine, Tokyo, Japan.
Hideki KoizumiDepartment of Ophthalmology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.
Tetsuju SekiryuDepartment of Ophthalmology, Fukushima Medical University, Fukushima, Japan.
Tomohiro IidaDepartment of Ophthalmology, Tokyo Women's Medical University, Tokyo, Japan.
Annabelle A OkadaDepartment of Ophthalmology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka-shi, Tokyo, Japan.
for Japan AMD Research Consortium (JARC)
Tokyo Women's Medical University · JPFukushima Medical University · JPKyorin University · JPNihon University · JPUniversity of the Ryukyus · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo assess 6-month outcomes of switching from aflibercept to faricimab in eyes with refractory neovascular age-related macular degeneration (nAMD) previously requiring monthly injections.

methodsThis multicenter retrospective study examined nAMD eyes receiving monthly aflibercept injections switched to faricimab administered monthly up to 4 injections followed by injections at a minimum of 2-month intervals as per drug labeling. Data regarding age, sex, number of previous injections, treatment intervals, and best-corrected visual acuity (BCVA) were collected. Central retinal thickness (CRT), subfoveal choroidal thickness (SFCT), and maximal pigment epithelial detachment (PED) height were measured by optical coherence tomography.

resultsThe study included 130 eyes of 124 patients. At 6 months, 53 eyes (40.8%) continued on faricimab treatment (Group 1), while 77 eyes (59.2%) discontinued faricimab for various reasons (Group 2) the most common being worse exudation. There were no significant differences between the two groups at baseline. In Group 1, CRT and SFCT significantly decreased at 1 month (P = 0.013 and 0.008), although statistical significance was lost at 6 months (P = 0.689 and 0.052). BCVA and maximal PED height showed no significant changes; however, mean treatment intervals were extended from 4.4 ± 0.5 weeks at baseline to 8.7 ± 1.7 weeks at 6 months (P < 0.001) in Group 1. No clear predictors of response were identified.

conclusionSwitching from aflibercept to faricimab allowed for extension of treatment intervals from monthly to bimonthly in roughly 40% of eyes, suggesting that faricimab may be considered in refractory nAMD cases.

Indexed as

Antibodies, BispecificMacular DegenerationRetinal DetachmentWet Macular DegenerationAngiogenesis InhibitorsFollow-Up StudiesHumansIntravitreal InjectionsReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsRetrospective StudiesTomography, Optical CoherenceTreatment OutcomeafliberceptAngiogenesis InhibitorsAntibodies, BispecificfaricimabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsAfliberceptAngiopoietin-2FaricimabNeovascular age-related macular degenerationVascular endothelial growth factor

Identifiers

PMID37668741
OpenAlexW4386438246

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.